Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

HIV-1 evolutionary dynamics under non-suppressive, 2nd-line protease-inhibitor containing antiretroviral therapy

View ORCID ProfileSteven A. Kemp, Oscar Charles, Anne Derache, Collins Iwuji, John Adamson, Katya Govender, Tulio de Oliveira, Nonhlanhla Okesola, Francois Dabis, Darren P. Martin, Deenan Pillay, Richard A. Goldstein, View ORCID ProfileRavindra K. Gupta on behalf of the French National Agency for AIDS and Viral Hepatitis Research (ANRS) 12249 Treatment as Prevention (TasP) Study Group
doi: https://doi.org/10.1101/2021.04.09.21254592
Steven A. Kemp
1Division of Infection & Immunity, University College London, London, UK
3Cambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID), Cambridge, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Steven A. Kemp
  • For correspondence: sk2137{at}cam.ac.uk Rkg20{at}cam.ac.uk
Oscar Charles
1Division of Infection & Immunity, University College London, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anne Derache
2Africa Health Research Institute, Durban, South Africa
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Collins Iwuji
2Africa Health Research Institute, Durban, South Africa
5Research Department of Infection and Population Health, University College London, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
John Adamson
2Africa Health Research Institute, Durban, South Africa
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Katya Govender
2Africa Health Research Institute, Durban, South Africa
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tulio de Oliveira
2Africa Health Research Institute, Durban, South Africa
6KRISP - KwaZulu-Natal Research and Innovation Sequencing Platform, UKZN, Durban, South Africa
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nonhlanhla Okesola
2Africa Health Research Institute, Durban, South Africa
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Francois Dabis
7INSERM U1219-Centre Inserm Bordeaux Population Health, Université de Bordeaux, France
8Université de Bordeaux, ISPED, Centre INSERM U1219-Bordeaux Population Health, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Darren P. Martin
9Department of Integrative Biomedical Sciences, University of Cape Town, South Africa
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Deenan Pillay
1Division of Infection & Immunity, University College London, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Richard A. Goldstein
1Division of Infection & Immunity, University College London, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ravindra K. Gupta
2Africa Health Research Institute, Durban, South Africa
3Cambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID), Cambridge, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Ravindra K. Gupta
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

Viral population dynamics in long term viraemic antiretroviral therapy (ART) treated individuals have not been well characterised. Prolonged virologic failure on 2nd-line protease inhibitor (PI) based ART without emergence of major protease mutations is well recognised, providing an opportunity to study within-host evolution.

Using next-generation Illumina short read sequencing and in silico haplotype reconstruction we analysed whole genome sequences from longitudinal plasma samples of eight chronically infected HIV-1 individuals failing 2nd-line regimens from the ANRS 12249 TasP trial, in the absence of high frequency major PI resistance mutations. Plasma drug levels were measured by HPLC. Three participants were selective for in-depth variant and haplotype analyses, each with five or more timepoints spanning at least 16 months. Recombination and linkage disequilibrium between haplotypes and genes was also explored.

During PI failure synonymous mutations were around twice as frequent as non-synonymous mutations across participants. Prior to or during exposure to PI, we observed several polymorphic amino acids in gag (e.g. T81A, T375N) which are have also been previously associated with exposure to protease inhibitor exposure. Although overall SNP frequency at abundance above 2% appeared stable across time in each individual, divergence from the consensus baseline sequence did increase over time. Non-synonymous changes were enriched in known polymorphic regions such as env whereas synonymous changes were more often observed to fluctuate in the conserved pol gene. Phylogenetic analyses of whole genome viral haplotypes demonstrated two common features: Firstly, evidence for selective sweeps following therapy switches or large changes in plasma drug concentrations, with hitchhiking of synonymous and non-synonymous mutations. Secondly, competition between multiple viral haplotypes that intermingled phylogenetically alongside soft selective sweeps. The diversity of viral populations was maintained between successive timepoints with ongoing viremia, particularly in env. Changes in haplotype dominance were often distinct from the dynamics of drug resistance mutations in reverse transcriptase (RT), indicating the presence of softer selective sweeps and/or recombination.

Large fluctuations in variant frequencies with diversification occur during apparently ‘stable’ viremia on non-suppressive ART. Reconstructed haplotypes provided further evidence for sweeps during periods of partial adherence, and competition between haplotypes during periods of low drug exposure. Drug resistance mutations in RT can be used as markers of viral populations in the reservoir and we found evidence for loss of linkage disequilibrium for drug resistance mutations, indicative of recombination. These data imply that even years of exposure to PIs, within the context of large stable populations displaying ongoing selective competition, may not precipitate emergence of major PI resistance mutations, indicating significant fitness costs for such mutations. Ongoing viral diversification within reservoirs may compromise the goal of sustained viral suppression.

Competing Interest Statement

RKG has received ad hoc consulting fees from Gilead, ViiV and UMOVIS Lab.

Clinical Trial

Clinicaltrials.gov: NCT01509508

Funding Statement

SAK is supported by the Bill and Melinda Gates Foundation: OPP1175094. RKG is supported by Wellcome Trust Senior Fellowship in Clinical Science: WT108082AIA.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Ethical approval was originally grant by the Biomedical Research Ethics Committee (BFC 104/11) at the University of KwaZulu-Natal, and the Medicines Control Council of South Africa for the TasP trial (Clinicaltrials.gov: NCT01509508; South African Trial Register: DOH-27-0512-3974). The study was also authorized by the KwaZulu-Natal Department of Health in South Africa. Written informed consent was obtained from all participants. Original ethical approval also included downstream sequencing of blood plasma samples and analysis of those sequences to better understand drug resistance. No additional ethical approval was required for this.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • Several figures have been updated with revised haplotype data and a new method was used to produce annotated phylogenies detailed in materials and methods. A new figure showing linkage disequilibrium has been added. Text significantly revised

Data Availability

All data has been provided as supplementary tables. Sequencing data can be provided upon reasonable request to the authors.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted August 13, 2021.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
HIV-1 evolutionary dynamics under non-suppressive, 2nd-line protease-inhibitor containing antiretroviral therapy
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
HIV-1 evolutionary dynamics under non-suppressive, 2nd-line protease-inhibitor containing antiretroviral therapy
Steven A. Kemp, Oscar Charles, Anne Derache, Collins Iwuji, John Adamson, Katya Govender, Tulio de Oliveira, Nonhlanhla Okesola, Francois Dabis, Darren P. Martin, Deenan Pillay, Richard A. Goldstein, Ravindra K. Gupta
medRxiv 2021.04.09.21254592; doi: https://doi.org/10.1101/2021.04.09.21254592
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
HIV-1 evolutionary dynamics under non-suppressive, 2nd-line protease-inhibitor containing antiretroviral therapy
Steven A. Kemp, Oscar Charles, Anne Derache, Collins Iwuji, John Adamson, Katya Govender, Tulio de Oliveira, Nonhlanhla Okesola, Francois Dabis, Darren P. Martin, Deenan Pillay, Richard A. Goldstein, Ravindra K. Gupta
medRxiv 2021.04.09.21254592; doi: https://doi.org/10.1101/2021.04.09.21254592

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • HIV/AIDS
Subject Areas
All Articles
  • Addiction Medicine (349)
  • Allergy and Immunology (668)
  • Allergy and Immunology (668)
  • Anesthesia (181)
  • Cardiovascular Medicine (2648)
  • Dentistry and Oral Medicine (316)
  • Dermatology (223)
  • Emergency Medicine (399)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (942)
  • Epidemiology (12228)
  • Forensic Medicine (10)
  • Gastroenterology (759)
  • Genetic and Genomic Medicine (4103)
  • Geriatric Medicine (387)
  • Health Economics (680)
  • Health Informatics (2657)
  • Health Policy (1005)
  • Health Systems and Quality Improvement (985)
  • Hematology (363)
  • HIV/AIDS (851)
  • Infectious Diseases (except HIV/AIDS) (13695)
  • Intensive Care and Critical Care Medicine (797)
  • Medical Education (399)
  • Medical Ethics (109)
  • Nephrology (436)
  • Neurology (3882)
  • Nursing (209)
  • Nutrition (577)
  • Obstetrics and Gynecology (739)
  • Occupational and Environmental Health (695)
  • Oncology (2030)
  • Ophthalmology (585)
  • Orthopedics (240)
  • Otolaryngology (306)
  • Pain Medicine (250)
  • Palliative Medicine (75)
  • Pathology (473)
  • Pediatrics (1115)
  • Pharmacology and Therapeutics (466)
  • Primary Care Research (452)
  • Psychiatry and Clinical Psychology (3432)
  • Public and Global Health (6527)
  • Radiology and Imaging (1403)
  • Rehabilitation Medicine and Physical Therapy (814)
  • Respiratory Medicine (871)
  • Rheumatology (409)
  • Sexual and Reproductive Health (410)
  • Sports Medicine (342)
  • Surgery (448)
  • Toxicology (53)
  • Transplantation (185)
  • Urology (165)